Athersys Hosting KOL Panel Event to Discuss TREASURE Data
June 08 2022 - 2:45PM
Business Wire
Webinar scheduled for June 14, 2022 at 5:00
p.m. ET
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company
developing MultiStem® (invimestrocel) for critical care
indications, announced today it will host a panel discussion with
leading neurology experts on Tuesday, June 14th at 5:00 p.m. ET.
The event will feature four key opinion leaders (KOLs) in the field
of stroke and a statistician to share their perspectives on the
topline data from the TREASURE study conducted by the Company’s
partner HEALIOS K.K. (Healios). The TREASURE study is a randomized,
double-blind placebo-controlled study evaluating MultiStem
administration for the treatment of ischemic stroke. The trial
enrolled 206 patients and was conducted by 48 sites in Japan.
Topline data were announced on May 20, 2022. The KOL panelists will
include:
- S. Thomas Carmichael, MD, PhD, Professor and Chair, Frances
Stark Chair, Department of Neurology, David Geffen School of
Medicine at UCLA
- David Chiu, MD, FAHA, Professor and Elizabeth Blanton Wareing
Chair in the Eddy Scurlock Stroke Center, Houston Methodist
Hospital, Weill Cornell Medical College
- Sean Savitz, MD, Professor and Director, UTHealth Houston
Institute for Stroke & Cerebrovascular Diseases
- Lawrence Wechsler, MD, Professor and Chair, Pennsylvania
Hospital, Perelman School of Medicine, University of
Pennsylvania
- LJ Wei, PhD, Professor of Biostatistics, Harvard
University
The panel will be moderated by Dr. Robert W. Mays, Vice
President of Regenerative Medicine and Head of the Neuroscience
programs at Athersys. Attendees may submit questions during the
webinar for the panelists.
KOL Panel Event and Webcast Information
Date and Time: Tuesday, June 14, 2022, at 5:00 p.m. ET To
register, please visit:
https://us06web.zoom.us/webinar/register/WN_oZVVGv_LTD-9J1ILDIzlmw
The presentation will be webcast live, and an archive of the
presentation will be available at www.athersys.com under the
investors' section soon after the call has ended.
About Ischemic Stroke
Stroke represents an area where the clinical need is
particularly significant, since it is a leading cause of death and
serious disability worldwide, with a substantially impaired quality
of life for many stroke victims. Currently, there are nearly 17
million people who suffer a stroke globally and more than two
million stroke victims each year in the United States, Europe and
Japan, combined. Ischemic strokes, which represent the most common
form of stroke, are caused by a blockage of blood flow in the brain
that cuts off the supply of oxygen and nutrients and can result in
long-term or permanent disability due to neurological damage.
Unfortunately, current therapeutic options for ischemic stroke
victims are limited, since the only available treatments,
administration of the clot dissolving agent tPA, or “thrombolytic,”
or surgical intervention to remove the clot, must be conducted
within several hours of the occurrence of the stroke. As a
consequence of this limited time window, only a small percentage of
stroke victims are treated with the currently available
therapy—most simply receive supportive or “palliative” care. The
long-term costs of stroke are substantial, with many patients
requiring extended hospitalization, extended physical therapy or
rehabilitation (for those patients that are capable of entering
such programs), and many require long-term institutional or family
care.
About MultiStem®
MultiStem® cell therapy (invimestrocel) is a patented
regenerative medicine product candidate in clinical development
that has shown the ability to promote tissue repair and healing in
a variety of ways, such as through the production of therapeutic
factors in response to signals of inflammation and tissue damage.
MultiStem therapy’s potential for multidimensional therapeutic
impact may distinguish it from traditional biopharmaceutical
therapies focused on a single mechanism of benefit. MultiStem
represents a unique "off-the-shelf" stem cell product candidate
that can be manufactured in a scalable manner, may be stored for
years in frozen form, and is administered without tissue matching
or the need for immune suppression. Based upon favorable outcome
data, its novel mechanisms of action, and favorable and consistent
tolerability data in clinical studies, we believe that MultiStem
therapy may provide a meaningful benefit to patients, including
those suffering from serious diseases and conditions with unmet
medical need.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
"off-the-shelf" stem cell product, initially for disease
indications in the neurological, inflammatory and immune,
cardiovascular, and other critical care indications and has several
ongoing clinical trials evaluating this potential regenerative
medicine product. Athersys has forged strategic partnerships and a
broad network of collaborations to further advance MultiStem cell
therapy toward commercialization. Investors and others should note
that we may post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220608006075/en/
Ivor Macleod Chief Financial Officer Tel: (216) 431-9900
ir@athersys.com
Karen Hunady Director of Corporate Communications and Investor
Relations Tel: (216) 431-9900 khunady@athersys.com
David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858)
717-2310 David.schull@russopartnersllc.com
Peter Vozzo ICR Westwicke Tel: (443) 213-0505
peter.vozzo@westwicke.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Sep 2023 to Sep 2024